Literature DB >> 20071126

A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.

Sarah Reinhardt1, Ming Zhao, Aleksander Mnatsakanyan, Linping Xu, Rebecca M Ricklis, Alice Chen, Judith E Karp, Michelle A Rudek.   

Abstract

A rapid and sensitive method was developed and validated using a liquid chromatographic method with tandem mass spectrometry detection (LC/MS/MS) for determination of veliparib (ABT-888) in plasma, bone marrow supernatant, and bone marrow cells. Sample preparation involved a single protein precipitation step by the addition of the sample with acetonitrile. Separation of veliparib and the internal standard, A620223.69, was achieved on a Atlantis dC(18) column (100mmx2.1mm, 3microm) column using a mobile phase consisting of acetonitrile-ammonium acetate (2mM) containing formic acid (0.1%, v/v) using isocratic flow at 0.2mL/min for 3min. The analyte and internal standard were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 5-1000nM. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods. This method was subsequently used to measure concentrations of veliparib in cancer patients receiving an oral daily dose of 10mg with demonstration of drug accumulation in the marrow compartment and in the target leukemia bone marrow cells. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20071126      PMCID: PMC2822340          DOI: 10.1016/j.jpba.2009.12.015

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

Review 1.  PARP inhibitors for cancer therapy.

Authors:  Nicola J Curtin
Journal:  Expert Rev Mol Med       Date:  2005-03-15       Impact factor: 5.600

Review 2.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.

Authors:  Prakash Jagtap; Csaba Szabó
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

3.  ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Authors:  Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

Review 4.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

5.  Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.

Authors:  Robert A Parise; Mohammad Shawaqfeh; Merrill J Egorin; Jan H Beumer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-07-31       Impact factor: 3.205

6.  Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Authors:  Shivaani Kummar; Robert Kinders; Martin E Gutierrez; Larry Rubinstein; Ralph E Parchment; Lawrence R Phillips; Jiuping Ji; Anne Monks; Jennifer A Low; Alice Chen; Anthony J Murgo; Jerry Collins; Seth M Steinberg; Helen Eliopoulos; Vincent L Giranda; Gary Gordon; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James H Doroshow
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

7.  Liquid Chromatographic Determination of NSC 737664 (ABT-888: an Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial.

Authors:  Lawrence R Phillips; Kimberly D Hill; Eva Majerova
Journal:  J Liq Chromatogr Relat Technol       Date:  2009-01       Impact factor: 1.312

8.  Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.

Authors:  Jeffrey M Albert; Carolyn Cao; Kwang Woon Kim; Christopher D Willey; Ling Geng; Dakai Xiao; Hong Wang; Alan Sandler; David H Johnson; Alexander D Colevas; Jennifer Low; Mace L Rothenberg; Bo Lu
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.

Authors:  Jodi A Muscal; Patrick A Thompson; Vincent L Giranda; Brian D Dayton; Joy Bauch; Terzah Horton; Leticia McGuffey; Jed G Nuchtern; Robert C Dauser; Brian W Gibson; Susan M Blaney; Jack M Su
Journal:  Cancer Chemother Pharmacol       Date:  2009-06-13       Impact factor: 3.333

  9 in total
  3 in total

1.  Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.

Authors:  Shailly Mehrotra; Mathangi Gopalakrishnan; Jogarao Gobburu; Jacqueline M Greer; Richard Piekarz; Judith E Karp; Keith Pratz; Michelle A Rudek
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

2.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

3.  A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Authors:  Keith W Pratz; Michelle A Rudek; Ivana Gojo; Mark R Litzow; Michael A McDevitt; Jiuping Ji; Larry M Karnitz; James G Herman; Robert J Kinders; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Douglas E Gladstone; Mark J Levis; Hua-Ling Tsai; Gary Rosner; Alice Chen; Scott H Kaufmann; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-22       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.